Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683923 | 0.92 | ACE2 (0.47) | FDPSACE2OPRM1CA1SPHK1 | |
| SCHEMBL28277613 | 0.90 | ACE2 (0.50) | FDPSACE2OPRM1SPHK1 | |
| SCHEMBL28277594 | 0.90 | ACE2 (0.50) | FDPSACE2OPRM1SPHK1 | |
| SCHEMBL28154759 | 0.90 | ACE2 (0.50) | FDPSACE2OPRM1SPHK1 | |
| SCHEMBL6181574 | 0.90 | ACE2 (0.50) | FDPSACE2OPRM1SPHK1 | |
| SCHEMBL100661 | 0.83 | — | — | |
| SCHEMBL28944520 | 0.82 | ACE2 (0.42) | FDPSACE2ALDH1A1DNM1TSHR | |
| SCHEMBL8368919 | 0.80 | ACE2 (0.36) | FDPSACE2ALDH1A1DNM1TSHR | |
| SCHEMBL18514502 | 0.80 | ACE2 (0.36) | FDPSACE2ALDH1A1DNM1TSHR | |
| SCHEMBL1369967 | 0.80 | ALDH1A1 (0.46) | FDPSACE2ALDH1A1CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | claimed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | claimed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | claimed |
| CN-106893581-B | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-106892915-B | Organic compound, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-02-22 | — | — | CN | disclosed |
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | disclosed |
| CN-106892914-B | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-106588946-B | 10-hydroxycamptothecine derivative, synthetic method and its application | 郑州大学 | 2019-01-22 | — | — | CN | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| CN-108101922-A | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-9809521-B2 | Cannabidinoid derivatives | SUTTER WEST BAY HOSPITALS (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2016-12-29 | — | — | US | disclosed |
| US-9254272-B2 | Resorcinol derivatives | SUTTER WEST BAY HOSPITALS (US) | 2016-02-09 | — | — | US | disclosed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | disclosed |
| EP-1212306-A2 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019797-A2 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
| US-4935426-A | FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1990-06-19 | — | — | US | disclosed |
| EP-0044979-B1 | DERIVATIVES OF 2-FLUORO-ALKANECARBOXYLIC ACIDS, THEIR PREPARATION, HERBICIDES COMPRISING THEM AND THEIR APPLICATION | BASF Aktiengesellschaft (DE) | 1983-11-02 | — | — | EP | disclosed |
| EP-0044979-A1 | Derivatives of 2-fluoro-alkanecarboxylic acids, their preparation, herbicides comprising them and their application | BASF Aktiengesellschaft (DE) | 1982-02-03 | — | — | EP | disclosed |
| EP-0010298-A1 | 1,2,4-Triazol-1-yl compounds, their preparation, fungicides, method for their preparation and method for combating fungi | BASF Aktiengesellschaft (DE) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | CNR1, CNR2, RCOR1 | FDPS 574/4885ACE2 2331/4885ALDH1A1 1955/4885 |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | FDPS 1343/4885ACE2 2975/4885ALDH1A1 3491/4885 |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | FDPS 1343/4885ACE2 2975/4885ALDH1A1 3491/4885 |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | CNR1, CNR2, RCOR1 | FDPS 574/4885ACE2 2331/4885ALDH1A1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.